A NEW ERA:
DEEP YET NON-INVASIVE BRAIN STIMULATION

The patented breakthrough technology of Brainsway™ launches a new era in the treatment of brain disorders. Brainsway offers a non-invasive yet highly effective treatment that activates deep brain structures. This is achieved using directed electromagnetic fields which generate excitation or inhibition of neurons deep inside the brain. The technology has been enthusiastically embraced by the international academic community, with over 60 clinical studies in leading institutions worldwide.

Unique Patented Coil Structure

Brainsway's dTMS (Deep Transcranial Magnetic Stimulation) technology is based on the H Coil, featuring a novel patented structure which maximizes electrical stimulation of deep brain regions. Unique features of the coil design include:

- Coil elements tangential to the head and close to target brain regions
- Flexible base suited to head shape
- Convergence of numerous electric pulses from various directions
- Coil elements parallel to target bundles
- Location of return paths of electrical impulses remote from target area



Brainsway technology is based on a patent registered by the U.S. National Institutes of Health (NIH). Brainsway has an exclusive license from the NIH for both the patent and the technology.

Brainsway

Deeper Stimulation







Electric Fields Generated by Figure 8 Coil vs. dTMS H1 Coil

Proven Efficacy

Studies show that stimulation of deeper (ventral) PFC structures significantly enhances antidepressant effects. The FDA has cleared Brainsway's dTMS technology for treatment of a wide range of Depression patients, from mild to severe cases, who did not benefit from antidepressants in the current depressive episode*. The indication is based on a 16-week DBPC (Double-Blind Placebo-Controlled) study covering over 230 subjects and showing a profound decline in HDRS-21, and significant remission and response rates.

Response and Remission Rates at Week 5*



* Remission – HDRS-21 Score < 10 ,
Response – Improvement of at least 50% from baseline

HDRS-21 Score Over Time



Slope (adjusted) of Change dTMS = -6.39 points
Slope (adjusted) of Change Sham = -3.28 points
P-value of Difference = 0.0080

* The Brainsway Deep TMS System is indicated by the FDA for the treatment of depressive episodes in adult patients suffering from Major Depressive Disorder, who failed to achieve satisfactory improvement from previous anti-depressant medication treatment in the current episode. FDA 510(k) No. 122888

Brainsway

For more information, scan the QR code
or visit **www.brainsway.com**.
Tel: 1-855-200-DTMS | **Email:** info@brainsway.com

USA-BRO-0001-00-V1.0